IVA

Inventiva S.A. is a French biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. The company's lead product candidate, lanifibranor, is a pan-PPAR agonist being evaluated for the treatment of MASH, a chronic liver disease with no approved therapies. Inventiva is also developing odiparcil for the treatment of mucopolysaccharidosis type VI, a rare genetic disorder. The company combines medicinal chemistry expertise with clinical development capabilities to advance its pipeline.